
Republic of the Philippines
Department of Health

OFFICE OF THE SECRETARY

SAN LAZARO COMPOUND. RIZAL AVENUE, STA. CRUZ, MANILA, PHILIPPINES
TEL. NOS. 111-6105 & 711-6061

<date>5/3/1992</date>

<doctype>ADMINISTRATIVE ORDER</doctype>
<docnum>No. 118 s. 1992</docnum> 

<subject>Subject: RULES AND REGULATIONS ON THE PROCESS OF REVIEW AND EVALUATION OF QUESTIONED VETERINARY DRUGS OR VETERINARY DRUG COMBINATIONS</subject>
<body>

	Pursuant to Section 3 (c) an 26 (a) of Republic Act No. 3720, as amended, the following rules and regulations are hereby promulgated to govern the review, evaluation and subsequent banning from the market of drugs or drug combinations which have been found unsafe, ineffective or of doubtful therapeutic value.

SECTION 1. DEFINITION OF TERMS
	1.1 “Veterinary Drugs” refer to: (1) articles recognized in the current official United States Pharmacopeia (USP). National Formulary (NF),official homeopathic pharmacopeia of the United States, official Philippine National Veterinary Drug Formulary (PNVDF), or any supplement to any of them; and (2) articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of diseases in terrestrial and aquatic animals: (3) articles (other than food) intended to affect the structure as commonest of any articles function of the animal body; and (4) articles intended for use as (1), (2) or (3) but do not include *text missing* their components, parts or accessories.

1.1.1 “Prescription or Ethical Veterinary Drugs and Products” refer to any drug preparation that is to be dispensed only upon written order of a duly-licensed veterinarian for the treatment of a condition or a diagnosed disease of animals. Such preparation are labeled Rx.

1.1.2 “Non-prescription Veterinary Drugs” or “Over-the-Counter Veterinary Drugs (OTC) or “Self-Service Veterinary Drugs (SS) refer to drug preparations that can be approved for animal use, even without the written order of a duly-licensed veterinarian.

1.2 “Veterinary Pharmaceutical” refers to the finished dosage form that contains the active ingredient(s), generally but not necessarily in association with inactive ingredients.
1.3 “Banning” refers to the act to prohibit the importation, manufacture, distribution, labeling , advertising and sale of a veterinary drug and product determined to be unsafe or ineffective as a consequence of veterinary drug combination, shall be removed from the registry.
SECTION 2. PROCEDURE FOR REVIEW AND EVALUATION
2.1 The process of review and evaluation is initiated when reliable scientific information indicates that a veterinary drug or combination of veterinary drugs is unsafe or ineffective or when there is a complaint by any party with substantial interest. The complaint should be properly documented and should include the following information:
	2.1.1 proper identification of the veterinary drugs or combination of veterinary drugs.
	2.1.2 description of reason to question its safety, efficacy, or therapeutic value.

2.2 Process of Hearing
	2.2.1 BFAD/BAI will publish the order and date off public hearing, which shall not be later than fifteen calendar days from the date of the publication of such order.
	2.2.2 The affected veterinary drug establishment must justify the continued BFAD/BAI registration of the veterinary drug and product on the basis of safety, efficacy and therapeutic value of active ingredients it contains. All integrated parties may present additional documentary evidence to clarify and supplement their position papers within thirty (30) calendar days from the date of the first public hearing. Verified and authentic evidence and the position papers shall constitute the direct evidence on the questioned veterinary drug

	2.2.3 All parties are entitled to cross-examine the witnesses that may be presented by the interested parties and affected veterinary drug establishment/s or witnesses who may be called by BFAD/BAI to establish the authenticity degree of accuracy and/or propriety of the reports or documents submitted in evidence or to testify to any material fact. For this purpose, BFAD/BAI shall require all parties concerned to submit a list of these witnesses and the time frame within which they will testify. This list and the time frame shall be strictly followed. Any witness not in the list shall not be allowed to testify. Failure to testify within the approved time from frame shall be deemed a waiver on the part of the interested party.
	2.2.5 The evidence presented in the public shall be evaluated by BAD/BAI on the basis of current standard for safety, efficacy and therapeutic value as defined. In joint Administrative Order, Department of health No. 111-A, s. 1991 and Department of Agriculture Order s. 1991. Rules and Regulations on Veterinary Drugs and Products.
	2.2.6 The BFAD/BAI shall make a recommendation to the Secretary of Health/Secretary  of Agriculture within thirty (30) days from termination of *text missing*
	2.2.7 The Secretary of Health/Secretary of Agriculture shall decide the final action to be taken and shall duly inform the parties concerned of the decision taken.

2.3 This procedure of review and evaluation does not preclude however the BFAD/BAI from submitting a recommendation to immediately ban a veterinary drug and a veterinary product in cases where there is a clear finding of serious or lethal toxicity constituting undue risk to animal health and public safety.
2.4 BFAD/BAI shall submit its finding and recommendation, together with records of substantial evidence to the Secretary of Health/Secretary of Agriculture for Immediate action.

SECTION 3. SEPARABILITY CLAUSE
	In case any provision of these rules and regulations is declared contrary to law or unconstitutional, other provisions which are not affected thereby shall continue to be in force and in effect.

SECTION 4. REPEALING CLAUSE
	This Order shall take effect fifteen (15) days after its publication in a newspaper of general circulation.
</body>
<sign>Senen C. Bacani, M.D.</sign>
<signtitle>Secretary of Health</signtitle>

<sign>Antonio O. Periquet, M.D.</sign>
<signtitle>Secretary of Health</signtitle>
